What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrot...
| Published in: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/7/1981 |
| _version_ | 1850405525761556480 |
|---|---|
| author | Urska Kamensek Maja Cemazar Simona Kranjc Brezar Tanja Jesenko Spela Kos Katarina Znidar Bostjan Markelc Ziva Modic Tilen Komel Tim Gorse Eva Rebersek Helena Jakopic Gregor Sersa |
| author_facet | Urska Kamensek Maja Cemazar Simona Kranjc Brezar Tanja Jesenko Spela Kos Katarina Znidar Bostjan Markelc Ziva Modic Tilen Komel Tim Gorse Eva Rebersek Helena Jakopic Gregor Sersa |
| author_sort | Urska Kamensek |
| collection | DOAJ |
| container_title | Pharmaceutics |
| description | DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach. |
| format | Article |
| id | doaj-art-e1458df429704fbe9b25838babe718fb |
| institution | Directory of Open Access Journals |
| issn | 1999-4923 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| spelling | doaj-art-e1458df429704fbe9b25838babe718fb2025-08-19T22:48:34ZengMDPI AGPharmaceutics1999-49232023-07-01157198110.3390/pharmaceutics15071981What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 VaccineUrska Kamensek0Maja Cemazar1Simona Kranjc Brezar2Tanja Jesenko3Spela Kos4Katarina Znidar5Bostjan Markelc6Ziva Modic7Tilen Komel8Tim Gorse9Eva Rebersek10Helena Jakopic11Gregor Sersa12Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaDNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach.https://www.mdpi.com/1999-4923/15/7/1981DNA vaccinationgene electrotransferCOVID-19 vaccineimmunological adjuvantinterleukin 12 |
| spellingShingle | Urska Kamensek Maja Cemazar Simona Kranjc Brezar Tanja Jesenko Spela Kos Katarina Znidar Bostjan Markelc Ziva Modic Tilen Komel Tim Gorse Eva Rebersek Helena Jakopic Gregor Sersa What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine DNA vaccination gene electrotransfer COVID-19 vaccine immunological adjuvant interleukin 12 |
| title | What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine |
| title_full | What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine |
| title_fullStr | What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine |
| title_full_unstemmed | What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine |
| title_short | What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine |
| title_sort | what we learned about the feasibility of gene electrotransfer for vaccination on a model of covid 19 vaccine |
| topic | DNA vaccination gene electrotransfer COVID-19 vaccine immunological adjuvant interleukin 12 |
| url | https://www.mdpi.com/1999-4923/15/7/1981 |
| work_keys_str_mv | AT urskakamensek whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT majacemazar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT simonakranjcbrezar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT tanjajesenko whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT spelakos whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT katarinaznidar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT bostjanmarkelc whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT zivamodic whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT tilenkomel whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT timgorse whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT evarebersek whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT helenajakopic whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine AT gregorsersa whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine |
